- Home
- NTIP vs TLPH Comparison
NTIP vs TLPH Comparison
Compare NTIP & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.49
HOLD
Current Price
$0.80
Company Overview
Basic Information| Metric | NTIP | TLPH |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 37.9M |
| IPO Year | 1998 | 2011 |
Fundamental Metrics
Financial Performance| Metric | NTIP | TLPH |
|---|---|---|
| Price | $1.49 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 52.8K | ★ 186.7K |
| Earning Date | 03-04-2026 | 03-30-2026 |
| Dividend Yield | ★ 6.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,000.00 | $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $0.38 |
| 52 Week High | $1.90 | $1.57 |
Technical Indicators
Market Signals| Indicator | NTIP | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 30.07 |
| Support Level | $1.24 | $0.78 |
| Resistance Level | $1.42 | $0.88 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 98.39 | 22.00 |
Price Performance
Historical Comparison NTIP
TLPH
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.